Hypertension can originate from early-life insults, whereas maternal melatonin therapy can be protective in a variety of models of programmed hypertension. We hypothesize that melatonin or melatonin receptor agonist agomelatine can prevent programmed hypertension in adult offspring induced by maternal exposure to continuous light. Female Sprague-Dawley pregnant rats randomly divided into four groups: controls, rats exposed to continuous light, exposed to continuous light plus treated with agomelatine (50 mg/day i.p.), and exposed to continuous light plus treated with 0.01% melatonin in drinking water throughout pregnancy and lactation period. Male offspring (n = 10/group) from three litters were examined at 12 weeks of age. Maternal continuous light exposure-induced hypertension in male offspring, which was prevented by melatonin or agomelatine therapy. Continuous light exposure did not affect melatonin pathway in adult offspring kidney. Genes that belong to the renin-angiotensin system (RAS), sodium transporters, AMP-activated protein kinase pathway, and circadian rhythm were potentially involved in the maternal exposure to continuous light-induced programmed hypertension. Maternal agomelatine therapy decreased Ace expression but increased Agtr2 and Mas1. Maternal melatonin therapy prevented the increases of Slc9a3, Slc12a3, and Atp1a1 expression induced by maternal continuous light exposure. In conclusion, maternal melatonin or agomelatine therapy prevents programmed hypertension induced by maternal exposure to continuous light. Agomelatine and melatonin reprogram the RAS and sodium transporters differentially, to prevent negative programming of continuous light. Our data highlight candidate genes and pathways in renal programming as targets for therapeutic Melatonin prevents light-induced hypertension, 2017, Vol. 97, No. 4 637 approaches to prevent programmed hypertension caused by early-life disturbance of the circadian rhythm.
Introduction
More and more people in the modern world become increasingly active during night time, resulting in circadian disruption. Night shift work can increase the risk of hypertension and adverse outcomes of pregnancy [1, 2] . However, the long-term effects of shift work during pregnancy to offspring remains unclear. Hypertension can come from early-life environmental insults, officially known as "the developmental origins of health and disease" (DOHaD) [3] . Blood pressure (BP) regulation is a complex process, primarily governed by the kidneys. The number of nephrons decreases in multiple animal models of developmental programming, indicating that developmental programming during nephrogenesis plays an important role in increasing susceptibility to adulthood hypertension [4, 5] . In the developing kidneys, maternal insults may impair nephrogenesis and induce renal programming, consequently leading to programmed hypertension [6, 7] . Accordingly, renal programming turns out to be a driving mechanism of programmed hypertension [6] [7] [8] . So far, several mechanisms, including oxidative stress, alterations of renin-angiotensin system (RAS) and sodium transporters, and nutrient-sensing signal have been reported to be associated with renal programming [6] [7] [8] .
Adult rats exposed to continuous light cause melatonin deficiency and leads to hypertension [9, 10] . It is unclear whether maternal continuous light exposure can induce programmed hypertension in adult offspring in a melatonin signaling pathway-dependent manner.
Melatonin, the most abundant hormone secreted by the pineal gland at night, regulates circadian rhythm. Other functions of melatonin, including its anti-inflammatory and antioxidant properties, epigenetic regulation, are linked to its regulation of BP [11, 12] . The kidney itself owns an intrinsic circadian clock involved in the control of sodium transport and BP [13, 14] . Thus, disturbance of the renal circadian clock is increasingly recognized as a risk factor for hypertension [14] .
The cellular circadian clock consists of interlinked positive and negative regulatory limbs [13, 14] . The positive limb includes the including Clock (encoding for circadian locomotor output cycles kaput) and Bmal1 (encoding for brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1) that activate transcription of their target genes. CLOCK/BMAL1 target genes include the Cry (encoding for cryptochrome) and Per (encoding for period) genes, whose proteins form the negative limb. Clock genes are expressed in the oocyte and in fetal organs during organogenesis [15] . Maternal melatonin signal plays a key role on establishing and entraining fetal circadian clocks [16] .
We reported previously that maternal melatonin treatment can protect adult offspring exposed to a variety of early-life insults from hypertension [17] [18] [19] [20] [21] [22] . Additionally, we observed that the protective mechanism of maternal melatonin therapy on programmed hypertension might be related to its regulation on the melatonin pathway in the offspring kidney [23] . Melatonin is known for its benefit on placenta homeostasis and consequently on pregnancy and fetal health [24, 25] . However, whether maternal melatonin therapy can regulate melatonin pathway and circadian clock in offspring kidney to prevent maternal continuous light exposure-induced programmed hypertension remains undetermined.
Melatonin receptor agonists have been reported to be helpful in stabilizing circadian rhythm and treat circadian rhythm-related disorders [26] . The DOHaD concept provides a shift on therapeutic approach from adulthood to early life, through so-called reprogramming [8] . Because of the essential role of continuous light exposure, renal programming, and melatonin signaling in the development of hypertension and the extended use of melatonin and its analogs in clinical practice, therefore, this study examined whether maternal melatonin or its analog agomelatine therapy prevented maternal continuous light exposure-induced programmed hypertension in adult offspring and explored the underlying mechanisms with a focus on the kidney.
Materials and methods

Animal models
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Institutional Animal Care and Use Committee of the Kaohsiung Chang Gung Memorial Hospital (IACUC approval number: 2 014 111 001). Virgin Sprague-Dawley (SD) rats (12-16 weeks old) were obtained (BioLASCO Taiwan Co., Ltd, Taipei, Taiwan) and housed and maintained in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Rats were exposed to a 12-h light/12-h dark photoperiod (lights on 0700-1900). Male SD rats were caged with individual females until mating was confirmed by observation of a vaginal plug. Pregnant rats were randomly divided into four groups (N = 3 per group): controls, rats exposed to continuous light (light), exposed to continuous light plus treated with agomelatine (light + A), and exposed to continuous light plus treated with melatonin (light + M). Male offspring from three independent litters (n = 10 in total) were examined at 12 weeks of age. The rats in the light group were exposed to a continuous light environment (lights on 24 h every day) for 6 weeks during pregnancy and lactation (i.e. from gestational day 1 to postnatal day 21). Agomelatine (50 mg/dose) was i.p. injection once a day prior to the onset of the dark phase of the 12-h light/dark cycle, based on the circadian rhythm resynchronization properties [27] , during pregnancy and lactation. Another continuous light exposure rats will receive 0.01% melatonin in drinking water throughout the pregnancy and lactation periods for a total of 6 weeks. The dose of melatonin was adopted according to our previous studies [17] [18] [19] . Melatonin was prepared twice weekly by dissolving the drug (10 mg) in 1 mL of 100% ethanol. For use, the stock solution was diluted with water to a final concentration of 0.01%. Each water bottle was wrapped with aluminum foil to protect the drug from light.
Because hypertension occurs at a higher rate and at an earlier age in males than females [28] , only male offspring was used in subsequent experiments. After birth, the subjects came from litters of 10 pups to standardize the received quantity of milk and maternal pup care. To prevent maternal rejection, pups were not weighted at birth. Each litter was left with the mother until weaning.
Blood pressure was measured in conscious rats by an indirect tail-cuff method (BP-2000; Visitech Systems, Inc., Apex, NC) [17] . To ensure accuracy and reproducibility, the rats were acclimated to restraint and tail-cuff inflation for 1 week prior to the experiment. Rats were placed on the specimen platform. Their tails were passed through tail cuffs and secured in place with tape. Following a 10-min warm-up period, 10 preliminary cycles were performed to allow the rats to adjust to the inflating cuff. A total of five cycles were recorded at each time point for each rat. Three stable measures were taken and averaged. Male offspring were euthanized by an i.p. overdose of pentobarbital at 12 weeks of age. The midline of the abdomen was opened, and the intestines were displaced laterally to allow visualization of the aorta. The aorta was cannulated with a 23-gauge butterfly needle, heparinized blood samples were collected, the vena cava was cut, and PBS was perfused until the kidneys were blanched. Perfused kidneys were harvested, decapsulated, divided into cortex and medulla, flash-frozen in liquid nitrogen, and stored at -80
• C for further analysis. Renal melatonin level was measured using an ELISA kit (MyBioSource, San Diego, CA) as previously described [23] . The intra-and interassay variations of the melatonin ELISA were 11.4% and 19.3%, respectively. Briefly, 100 mg kidney cortex was homogenized in 500 μL PBS and protein concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA). After two freeze-thaw cycles were performed, tissue homogenate samples were centrifuged. Duplicate determinations in 100 μL of supernatant samples were made, and the average of two measurements was used in subsequent statistical analysis of the data. The melatonin level was quantified spectrophotometrically at 450 nm. The results were expressed as pg melatonin per mg of protein.
High performance liquid chromatography
Plasma L-arginine, L-citrulline, asymmetric dimethylarginine (ADMA, an endogenous inhibitor of nitric oxide [NO] synthase), and symmetric dimethylarginine (SDMA, an isomer of ADMA) levels were measured using HPLC ([high performance liquid chromatography] HP series 1100; Agilent Technologies Inc, Santa Clara, CA) with the o-phtalaldehyde-3-mercaptoprionic acid derivatization reagent described previously [17] . Standards contained concentrations of 1-100 mM L-arginine, 1-100 mM L-citrulline, 0.5-5 mM ADMA, and 0.5-5 mM SDMA. The recovery rate was approximately 95%.
Quantitative real-time polymerase chain reaction RNA was extracted as previously described procedures [22] . Twostep quantitative real-time polymerase chain reaction (RT-qPCR) was conducted using the QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA, USA) and the iCycler iQ Multi-color Real- Ren = renin, Atp6ap2 = prorenin receptor (PRR), Agt = angiotensinogen, Ace = angiotensin converting enzyme, Ace2 = angiotensin converting enzyme, Agtr1 = angiotensin II type 1 receptor, Agtr2 = angiotensin II type 2 receptor, Mas1 = angiotensin (1-7) receptor MAS, Prkaa2 = protein kinase AMPactivated catalytic subunit α2, Prkab2 = protein kinase AMP-activated catalytic subunit β2, Prkag3 = protein kinase AMP-activated catalytic subunit γ 3, Ppargc1a = peroxisome proliferator-activated receptor gamma coactivator 1-α, Bmal1 = brain and muscle aryl-hydrocarbon receptor nuclear translocatorlike 1, Cry1 = cryptochrome 1, Cry2 = cryptochrome 2, Per1 = period 1, Per2 = period 2, Per3 = period 3, Ck1e = casein kinase 1 epsilon, Nr1d1 = nuclear receptor subfamily 1, group D member 1 (also known as Rev-Erb-α), Slc9a3 = type 3 sodium hydrogen exchanger, Slc12a3 = Na
Time PCR Detection System (Bio-Rad, Hercules, CA). We analyzed several components of RAS in this study, including renin (Ren), prorenin receptor (atp6ap2), angiotensinogen (Agt), angiotensin converting enzyme-1 (Ace), angiotensin converting enzyme-2 (Ace2), angiotensin II type 1 receptor (Agtr1a), angiotensin II type 2 receptor (Agtr2), and angiotensin (1-7) receptor Mas1. Next, expression of four sodium transporters, namely, type 3 sodium hydrogen exchanger (Slc9a3), Na + /Cl − cotransporter (Slc12a3), Na-K-2Cl cotransporter (Slc12a1), and Na
was analyzed. Moreover, several core clock genes were studied, including Clock and Bmal1 of the positive limb; and Cry1, Cry2, Per1, Per2, and Per3 of the negative limb. In addition to these, other clockcontrolled genes, such as casein kinase 1 epsilon (Ck1e) and nuclear receptor subfamily 1, group D member 1 (Nr1d1) were analyzed.
In the nutrient-sensing signal, we analyzed AMP-activated protein kinase (AMPK) pathway, including protein kinase AMP-activated catalytic subunit α2 (Prkaa2), β2 (Prkab2), and γ 3 (Prkag3), and their downstream signal peroxisome proliferator-activated receptor gamma coactivator 1-α (Ppargc1a). The 18S rRNA gene (Rn18s) was used as a reference. All samples were run in duplicate. Primer sequences are provided in Table 1 . To quantify the relative gene expression, the comparative threshold cycle (C T ) method was employed. For each sample, the average C T value was subtracted from the corresponding average Rn18s value, calculating the C T . C T was calculated by subtracting the average control C T value from the average experimental C T . The fold-increase of the experimental sample relative to the control was calculated using the formula 2 − CT .
Western blot
Western blot analysis was performed as described previously [23] . Three melatonin receptors, including melatonin receptor-1 (MT1) and -2 (MT2) and retinoid-related orphan receptor-α (RORα), were analyzed. We used the following antibodies: a goat anti-rat MT1 antibody (1:1000, overnight incubation; Santa Cruz Biotechnology, Santa Cruz, CA; SC13186); a rabbit anti-rat MT2 antibody (1:1000, overnight incubation; Biorbyt, AllBio Science Inc., Taichung, Taiwan; ORB11086); and a rabbit anti-rat RORα antibody (1:2000, overnight incubation; Proteintech Group, Inc., Chicago, IL; 10616-1-AP). Bands of interest were visualized using ECL reagents (PerkinElmer, Waltham, MA) and quantified by densitometry (Quantity One Analysis software; Bio-Rad) as integrated optical density (IOD) after subtraction of background. The IOD was factored for Ponceau red staining to correct for any variations in total protein loading. The protein abundance was represented as IOD/PonS.
Statistical analysis
Data are given as mean ± SEM. For most parameters, statistical analysis was done using one-way ANOVA with Tukey post hoc test for multiple comparisons. Blood pressure was analyzed by twoway repeated-measures ANOVA and Tukey post hoc test. A P-value of 0.05 was considered statistically significant. All analyses were performed using the Statistical Package for the Social Sciences software (SPSS, Chicago, IL).
Results
Litter sizes were not significantly altered by maternal exposure to continuous light, agomelatine, and melatonin therapy (pups per litter: control = 11.4 ± 0.4; light group = 11.4 ± 1.1; light + A group = 11 ± 0.6; light + M group = 11 ± 0.8). Body weight (BW) and kidney weight were lower in the offspring exposed to continuous light than controls. However, mortality rates and kidney weight-to-BW ratio did not differ among the four groups. As shown in Figure 1 , systolic BP was comparable in the four groups before 6 weeks of age. The systolic BP of the light group was significantly greater than that of the control from 8 to 12 weeks of age, which was prevented by maternal agomelatine or melatonin therapy. A significant reduction in systolic BP, diastolic BP, and mean arterial pressure was measured in the light + A and light + M groups versus the light group at 12 weeks of age (Table 2) .
Next, we examined a number of mechanisms which might be involved in the continuous light-induced programmed hypertension and protective effects of melatonin and agomelatine based on published data. First, we looked at the melatonin synthesis and its receptors. We found that protein levels of MT1, MT2, and RORα, and renal melatonin level did not differ at 12 weeks of age among the four groups (Figure 2 ). These observations suggest that continuous light exposure did not affect melatonin pathway in adult offspring kidney.
We and others previously demonstrated that an early shift in the ADMA-mediated NO-reactive oxygen species balance toward increased oxidative stress leads to programmed hypertension in later life [29] [30] [31] . However, maternal continuous light exposure, agomelatine, and melatonin therapy had no effect on plasma levels of L-citrulline, L-arginine, ADMA, and SDMA (Table 3) . Therefore, alterations in L-arginine-ADMA-NO pathway might not be a major factor contributing to the programming of hypertension in this model. Also, activation of RAS and sodium transporters are important mechanisms involved in programmed hypertension [4] [5] [6] [7] . We then performed qPCR to further validate the transcripts that are related to these two pathways. Renal mRNA expression of renin, Atp6ap2, Agt, Ace, Ace2, and Agtr1 was significantly increased in offspring exposed to continuous light. Maternal agomelatine therapy decreased Ace and Ace2 expression but increased Agtr2 and Mas1. Maternal melatonin therapy just reduced Ace expression. ( Figure 3A) . As for sodium transporters, continuous light exposure upregulated Slc9a3, Slc12a3, and Atp1a1 expression in the kidney, which maternal melatonin therapy prevented ( Figure 3B ).
Given that light and melatonin controls circadian clock and that renal circadian rhythm related to hypertension, we next analyzed core clock genes and clock-controlled genes in the offspring kidney ( Figure 3C ). We found that renal mRNA expression of Clock, Bmal1, Cry2, Per1, Per2, and Ck1e was higher in the light group compared to the control. Maternal agomelatine therapy downregulated mRNA expression of the positive element Baml, and Per1, Per2, and Per3 of the negative limb. Melatonin therapy significantly downregulated Finally, mindful of the fact that nutrient-sensing pathway, like AMPK pathway, is considered a common mechanism underlying programmed hypertension [32] , we thus examined mRNA expression of Prkaa2, Prkab2, Prkag3, and Ppargc1a. Our data showed that continuous light exposure significantly increased the renal mRNA expression of all four of them compared with those in controls, while maternal agomelatine therapy decreased Prkaa2 and Ppargc1a expression.
Discussion
Our study provides new insight into the mechanisms by which early agomelatine or melatonin therapy provides a long-term protection on maternal exposure to continuous light-induced programmed hypertension in adult male offspring. The major findings can be summarized as follows: (1) exposure of the mother to continuous light-induced programmed hypertension in adult offspring, which maternal agomelatine or melatonin therapy prevented; (2) continuous light exposure did not affect melatonin pathway in adult offspring kidney; (3) genes that belong to the RAS, sodium transporters, AMPK pathway, and circadian rhythm were potentially involved in the continuous light exposure-induced programmed hypertension; (4) in continuous light exposure-induced programmed hypertension, the components of RAS, sodium transporters, and AMPK pathway were differentially regulated by agomelatine and melatonin therapy, to reprogram the development of hypertension.
Despite the hypertensive effects of continuous light exposure in adult rats [33, 34] , limited data are available regarding dams exposed to continuous light causing elevation of BP in their adult offspring. On the other hand, whether melatonin receptor agonists can prevent hypertension caused by disrupted circadian rhythm remains unclear [35] , even with the reported BP lowering effects of melatonin [11, [17] [18] [19] [20] [21] [22] [23] . To the best of our knowledge, this study is the first to show that maternal melatonin and agomelatine therapy can prevent programmed hypertension of adult offspring whose mother was exposed to continuous light. In adult rats, hypertension can be induced over 2 weeks continuous light exposure [33] . Nevertheless, this study showed that programmed hypertension develops in the offspring exposed to continuous light as long as 8 weeks after birth. These data suggest that mechanisms involved in the developmental programming of hypertension might be different between these two models.
Continuous light exposure has been considered as an experimental model of melatonin-deficient hypertension [10] . Previous studies showed that exposure of pregnant rats to continuous light suppressed plasma melatonin circadian rhythm in the mother, fetal, and adult offspring [10, 36, 37] . We observed that melatonin level and melatonin receptor expression were not altered in the offspring kidney at 12 weeks of age. Our findings implicate that the renal programming is not specific to a single factor (i.e. melatonin pathway), and therefore other mechanisms of programmed hypertension deserves further clarification.
So far, some particular mechanisms contributing to programmed hypertension have been studies in the kidney [5] [6] [7] [8] 29, 38] , such as oxidative stress, alterations of RAS and sodium transporters, and nutrient-sensing signal. Although a previous report showing that continuous light-induced hypertension is related to oxidative stress [35] , our data implicated that ADMA-NO pathway might not be a major underlying mechanism. In addition, activation of RAS in the kidney has been considered as a key mechanism for the development of hypertension [39] . This concept is supported by our data showing that continuous light exposure-induced programmed hypertension is associated with the increases of renal mRNA expression levels of renin, Atp6ap2, Agt, Ace, and Agtr1, which promote vasoconstriction in favor of developing hypertension. Our findings are consistent with previous studies demonstrating that ACE inhibitor is protective against continuous light exposure-induced hypertension [33, 34] . In contrast, maternal agomelatine therapy decreased Ace expression but increased Agtr2 and Mas1. That is, agomelatine appears to activate the ACE2-Ang-(1-7)-Mas receptor axis opposes the actions of the classical RAS axis, leading to BP-lowering effect. Next, early-life insults can induce inappropriate sodium reabsorption that increase the vulnerability to develop hypertension in later life [6, 7] . Though it is well known that circadian clock controls renal sodium handling [14] , very few studies have investigated sodium transporters in response to continuous light exposure. Our study is the first to show that continuous light exposure increased renal mRNA expression levels of Slc9a3, Slc12a3, and Atp1a1, which can be prevented by maternal melatonin therapy. These findings suggest that agomelatine and melatonin deprogram the RAS and sodium transporters differentially, to prevent programmed hypertension.
Emerging evidence suggested that a number of clock genes in the kidney play an integral role in the development of hypertension, such as Baml, Ck1e, Cry1, Per1, and Per2 [13, 14, 40] . We observed that continuous light exposure induced renal mRNA of Clock, Bmal1, Cry2, Per1, Per2, and Ck1e. The increases of Baml, and Per1, Per2, and Per3 expression can be prevented by agomelatine therapy. Unlike agomelatine, melatonin therapy reduced Clock, Baml, Cry1, and Ck1e. It is possible that the protective effects of melatonin on hypertension caused by disrupted circadian rhythm are coming, at least in part, from receptor-independent actions.
Our study has a few limitations. First, we did not examine other organs are responsible for BP regulation. The protective effects of agomelatine or melatonin therapy may be derived from other organs, such as the brain, heart, and vasculature. Despite we normalized the litter sizes, each pup might not receive identical maternal care, milk composition, and milk consumption. Since birth weight and growth rate were not recorded in this study, the implications of intra-uterine growth retardation and catch-up growth on continuous light-induced programmed hypertension deserve further clarification. Next, we did not conduct the control + melatonin and control + agomelatine groups. Thus, the long-term programmed effects of melatonin or agomelatine on normal controls deserve further evaluation. Another limitation is that clock genes expression was measured only at one point, it is not possible to infer whether the differences among the experimental groups are due to differences in gene expression degree or to a phase shift. Finally, we did not examine other dosing and routes of administration, and test other melatonin receptor agonists, whether these changes elicit same reprogramming effects on continuous light exposure-induced hypertension deserve further evaluation.
In conclusion, early agomelatine or melatonin therapy provides protection against maternal exposure to continuous light-induced programmed hypertension. Maternal agomelatine and melatonin therapy reprogram the RAS and sodium transporters differentially to prevent maternal exposure to continuous light-induced programmed hypertension. By providing new information of candidate pathways on BP regulation whose effects can be modified by agomelatine or melatonin, our results are of significance to the development of novel interventions in the prevention of programmed hypertension in children exposed to maternal night shift work and circadian disruption.
